Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Closes on Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Complete Genomics announced today that it has closed its public offering of more than 6.3 million shares of its common stock at $12.50 per share.

The total number of shares sold includes 825,000 shares purchased by the offering's underwriters at $12.50 per share to cover over-allotments. The Mountain View, Calif., company had previously said that with the exercise of the over-allotment option, the net proceeds from the offering would be about $73.8 million.

Jefferies and UBS Investment Bank were joint book-running managers, while Baird and Cowen served as co-managers for the offering.

In a filing with the US Securities and Exchange Commission last month, Complete Genomics said that about $20 million of the net proceeds will be used to expand its sequencing and computing capacity in its facilities in Mountain View and Santa Clara, Calif. About $15 million will go toward further development of its sequencing technology and services, and $15 million will be used for sales and marketing activities.

The remainder of the net proceeds will go toward working capital and general corporate purposes.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.